|
1
|
Prevention and management of osteoporosis,
. World Health Organ Tech Rep Ser. 921:1–164, back cover.
2003.PubMed/NCBI
|
|
2
|
Lane NE: Epidemiology, etiology, and
diagnosis of osteoporosis. Am J Obstet Gynecol. 194(2): Suppl.
S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Teitelbaum SL: Bone Resorption by
Osteoclasts. Science. 289:1504–1508. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Novack DV and Teitelbaum SL: The
osteoclast: Friend or foe? Annu Rev Pathol. 3:457–484. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Teitelbaum SL and Ross FP: Genetic
regulation of osteoclast development and function. Nat Rev Genet.
4:638–649. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pérez-Sayáns M, Somoza-Martín JM,
Barros-Angueira F, Rey JM and García-García A: RANK/RANKL/OPG role
in distraction osteogenesis. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 109:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chambers TJ: Regulation of the
differentiation and function of osteoclasts. J Pathol. 192:4–13.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takeshita S, Kaji K and Kudo A:
Identification and characterization of the new osteoclast
progenitor with macrophage phenotypes being able to differentiate
into mature osteoclasts. J Bone Miner Res. 15:1477–1488. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng X and Teitelbaum SL: Osteoclasts: New
Insights. Bone Res. 1:11–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yasuda H: RANKL, a necessary chance for
clinical application to osteoporosis and cancer-related bone
diseases. World J Orthop. 4:207–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiong J and O'Brien CA: Osteocyte RANKL:
New insights into the control of bone remodeling. J Bone Miner Res.
27:499–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leung PC and Siu WS: Herbal treatment for
osteoporosis: A current review. J Tradit Complement Med. 3:82–87.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Putnam SE, Scutt AM, Bicknell K, Priestley
CM and Williamson EM: Natural products as alternative treatments
for metabolic bone disorders and for maintenance of bone health.
Phytother Res. 21:99–112. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong RW and Rabie AB: Traditional Chinese
medicines and bone formation-a review. J Oral Maxillofac Surg.
64:828–837. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li F, Yang Y, Zhu P, Chen W, Qi D, Shi X,
Zhang C, Yang Z and Li P: Echinacoside promotes bone regeneration
by increasing OPG/RANKL ratio in MC3T3-E1 cells. Fitoterapia.
83:1443–1450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adami S, Idolazzi L, Fracassi E, Gatti D
and Rossini M: Osteoporosis Treatment: When to discontinue and when
to re-start. Bone Res. 4:323–335. 2013. View Article : Google Scholar
|
|
18
|
Rufus P, Mohamed N and Shuid AN:
Beneficial effects of traditional Chinese medicine on the treatment
of osteoporosis on ovariectomised rat models. Curr Drug Targets.
14:1689–1693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pang Z, Zhi-Yan Z, Wang W, Ma Y, Feng-Ju
N, Zhang X and Han C: The advances in research on the
pharmacological effects of Fructus Ligustri Lucidi. Biomed Res Int.
2015:2818732015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Leung PC, Che CT, Chow HK, Wu CF
and Wong MS: Improvement of bone properties and enhancement of
mineralization by ethanol extract of Fructus Ligustri Lucidi. Br J
Nutr. 99:494–502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li G, Zhang XA, Zhang JF, Chan CY, Yew DT,
He ML, Lin MC, Leung PC and Kung HF: Ethanol extract of Fructus
Ligustri Lucidi promotes osteogenesis of mesenchymal stem cells.
Phytother Res. 24:571–576. 2010.PubMed/NCBI
|
|
22
|
Lyu Y, Feng X, Zhao P, Wu Z, Xu H, Fang Y,
Hou Y, Denney L, Xu Y and Feng H: Fructus Ligustri Lucidi (FLL)
ethanol extract increases bone mineral density and improves bone
properties in growing female rats. J Bone Miner Metab. 32:616–626.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng X, Lyu Y, Wu Z, Fang Y, Xu H, Zhao P,
Xu Y and Feng H: Fructus ligustri lucidi ethanol extract improves
bone mineral density and properties through modulating calcium
absorption-related gene expression in kidney and duodenum of
growing rats. Calcif Tissue Int. 94:433–441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bian Q, Liu SF, Huang JH, Yang Z, Tang DZ,
Zhou Q, Ning Y, Zhao YJ, Lu S, Shen ZY and Wang YJ: Oleanolic acid
exerts an osteoprotective effect in ovariectomy-induced
osteoporotic rats and stimulates the osteoblastic differentiation
of bone mesenchymal stem cells in vitro. Menopause. 19:225–233.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Y, Huai Y, Jin J, Geng M and Li JX:
Quinoxaline derivative of oleanolic acid inhibits osteoclastic bone
resorption and prevents ovariectomy-induced bone loss. Menopause.
18:690–697. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rodan GA and Martin TJ: Therapeutic
approaches to bone diseases. Science. 289:1508–1514. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bruyère O and Reginster JY: Monitoring of
osteoporosis therapy. Best Pract Res Clin Endocrinol Metab.
28:835–841. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mizoguchi T, Muto A, Udagawa N, Arai A,
Yamashita T, Hosoya A, Ninomiya T, Nakamura H, Yamamoto Y, Kinugawa
S, et al: Identification of cell cycle-arrested quiescent
osteoclast precursors in vivo. J Cell Biol. 184:541–554. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boyce BF and Xing L: Functions of
RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem
Biophys. 473:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siddiqi MH, Siddiqi MZ, Ahn S, Kang S, Kim
YJ, Sathishkumar N, Yang DU and Yang DC: Ginseng saponins and the
treatment of osteoporosis: Mini literature review. J Ginseng Res.
37:261–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rahman MM, Bhattacharya A and Fernandes G:
Conjugated linoleic acid inhibits osteoclast differentiation of
RAW264.7 cells by modulating RANKL signaling. J Lipid Res.
47:1739–1748. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hou GQ, Guo C, Song GH, Fang N, Fan WJ,
Chen XD, Yuan L and Wang ZQ: Lipopolysaccharide (LPS) promotes
osteoclast differentiation and activation by enhancing the MAPK
pathway and COX-2 expression in RAW264.7 cells. Int J Mol Med.
32:503–510. 2013.PubMed/NCBI
|
|
34
|
Suh KS, Rhee SY, Kim YS, Lee YS and Choi
EM: Xanthohumol modulates the expression of osteoclast-specific
genes during osteoclastogenesis in RAW264.7 cells. Food Chem
Toxicol. 62:99–106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim N, Kadono Y, Takami M, Lee J, Lee SH,
Okada F, Kim JH, Kobayashi T, Odgren PR, Nakano H, et al:
Osteoclast differentiation independent of the TRANCE-RANK-TRAF6
axis. J Exp Med. 202:589–595. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Eriksen EF: Cellular mechanisms of bone
remodeling. Rev Endocr Metab Disord. 11:219–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakashima T, Hayashi M and Takayanagi H:
New insights into osteoclastogenic signaling mechanisms. Trends
Endocrinol Metab. 23:582–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ikeda F, Nishimura R, Matsubara T, Tanaka
S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, et
al: Critical roles of c-Jun signaling in regulation of NFAT family
and RANKL-regulated osteoclast differentiation. J Clin Invest.
114:475–484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Winograd-Katz SE, Brunner MC, Mirlas N and
Geiger B: Analysis of the signaling pathways regulating
Src-dependent remodeling of the actin cytoskeleton. Eur J Cell
Biol. 90:143–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Recchia I, Rucci N, Funari A, Migliaccio
S, Taranta A, Longo M, Kneissel M, Susa M, Fabbro D and Teti A:
Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo
[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in
vitro. Bone. 34:65–79. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee EJ, Kim JL, Gong JH, Park SH and Kang
YH: Inhibition of osteoclast activation by phloretin through
disturbing αvβ3 integrin-c-Src pathway. Biomed Res Int.
2015:6801452015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ullevig SL, Kim HS, Nguyen HN, Hambright
WS, Robles AJ, Tavakoli S and Asmis R: Ursolic acid protects
monocytes against metabolic stress-induced priming and dysfunction
by preventing the induction of Nox4. Redox Biol. 2:259–266. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Alvarado HL, Abrego G, Garduño-Ramirez ML,
Clares B, Calpena AC and García ML: Design and optimization of
oleanolic/ursolic acid-loaded nanoplatforms for ocular
anti-inflammatory applications. Nanomedicine. 11:521–530.
2015.PubMed/NCBI
|
|
44
|
Yao W, Dai J, Zheng C, Bao B, Cheng H,
Zhang L, Ding A and Li W: Quality assessment of Fructus Ligustri
Lucidi by the simultaneous determination of six compounds and
chemometric analysis. J Sep Sci. 38:1822–1827. 2015. View Article : Google Scholar : PubMed/NCBI
|
